Ascendis Pharma total liabilities fall to EUR 926.73 million from EUR 1.47 billion
ASND•Ascendis Pharma reported total liabilities of EUR 926.73 million at September 30, 2026, down from EUR 1.47 billion at December 31, 2025. Assets rose to EUR 2.43 billion, and cash and cash equivalents increased to EUR 964.36 million.
1. Assets and liabilities
Ascendis Pharma’s assets rose to EUR 2.43 billion at September 30, 2026, from EUR 1.3 billion at December 31, 2025, while total liabilities fell to EUR 926.73 million from EUR 1.47 billion. Cash and cash equivalents increased to EUR 964.36 million from EUR 616.04 million.
2. Convertible notes and taxes
The May conversion of 2.25% convertible notes due 2028 transferred EUR 719.4 million of liabilities to equity, with no impact on profit. Deferred tax assets reached EUR 651.89 million, primarily reflecting EUR 679.59 million from reversals of prior-period write-downs.
